Sample collection
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Squamous Cell Anal Carcinoma
Conditions
Squamous Cell Anal Carcinoma, Metastatic Squamous Cell Carcinoma
Trial Timeline
Jun 9, 2022 → Nov 1, 2026
NCT ID
NCT04894370About Sample collection
Sample collection is a phase 2 stage product being developed by Novartis for Squamous Cell Anal Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04894370. Target conditions include Squamous Cell Anal Carcinoma, Metastatic Squamous Cell Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04894370 | Phase 2 | Recruiting |
Competing Products
20 competing products in Squamous Cell Anal Carcinoma